M.P. has acted as scientific advisor for the development of the glibenclamide-glyburide suspension named AMGLIDIA in the European Union. The other authors have declared no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Hattersley et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: